Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2021, Servier employs 21,800 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient's voice at the heart of its activities.

A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.

Its first Irish subsidiary, Servier Laboratories (Ireland) Ltd, was founded in Dublin in 1974 with the aim of bringing innovative treatments to Irish patients and helping with chronic disease management and cancer. In 1989, with just 12 staff, Servier (Ireland) Industries Ltd was established in Arklow, Co. Wicklow. Over 30 years later this beautifully designed manufacturing facility is the Servier Group’s second largest site globally and home to 450 employees. At present over 100,000 Irish patients benefit from Servier treatments daily. 
----
To report a suspected adverse event with a Servier drug, please visit: 
https://servier.ie/laboratories/contact-us-laboratories/#report-a-side-effect

Servier Ireland

Org chart

Similar companies